Literature DB >> 9520455

Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells.

T S Migone1, N A Cacalano, N Taylor, T Yi, T A Waldmann, J A Johnston.   

Abstract

Interleukin 2 (IL-2) rapidly induces tyrosine phosphorylation of intracellular substrates, including the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Jak1), Jak3, signal transducer/activator of transcription proteins, and Shc, but the mechanism underlying dephosphorylation of these proteins is not known. The src homology 2 (SH2) containing tyrosine phosphatase 1 (SHP-1) is recruited by several hematopoietic surface receptors indicating that this phosphatase plays an important role as a regulator of signaling. We have found that IL-2 induces association of SHP-1 with the IL-2 receptor complex, and that once SHP-1 is recruited to the activated receptor it is able to decrease tyrosine phosphorylation of IL-2Rbeta and the associated tyrosine kinases Jak1 and Jak3. This dephosphorylation is specific as expression of a catalytically inactive form of SHP-1, or expression of the related phosphatase SHP-2 did not result in dephosphorylation of the IL-2 receptor components. Furthermore, we have found that SHP-1 expression is greatly decreased or undetectable in a number of IL-2 independent HTLV-I transformed T cell lines that exhibit constitutive Jak/signal transducer/activator of transcription activation. In HTLV-I infected T cells, down-regulation of SHP-1 expression was also found to correlate with the acquisition of IL-2 independence. These observations suggest that SHP-1 normally functions to antagonize the IL-2 signal transduction pathway and that HTLV-I infection and oncogenic transformation can lead to loss of SHP-1 expression resulting in constitutive activation of IL-2 regulated T cell responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520455      PMCID: PMC19925          DOI: 10.1073/pnas.95.7.3845

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Applications of retrovirus-mediated expression cloning.

Authors:  M Onishi; S Kinoshita; Y Morikawa; A Shibuya; J Phillips; L L Lanier; D M Gorman; G P Nolan; A Miyajima; T Kitamura
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

2.  Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness.

Authors:  U Lorenz; K S Ravichandran; S J Burakoff; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

3.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.

Authors:  X Piao; R Paulson; P van der Geer; T Pawson; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 4.  The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling.

Authors:  W J Leonard
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

5.  Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation.

Authors:  M C Friedmann; T S Migone; S M Russell; W J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor beta chain.

Authors:  M Adachi; M Ishino; T Torigoe; Y Minami; T Matozaki; T Miyazaki; T Taniguchi; Y Hinoda; K Imai
Journal:  Oncogene       Date:  1997-04-03       Impact factor: 9.867

7.  Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1.

Authors:  H Jiao; K Berrada; W Yang; M Tabrizi; L C Platanias; T Yi
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

8.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.

Authors:  T S Migone; J X Lin; A Cereseto; J C Mulloy; J J O'Shea; G Franchini; W J Leonard
Journal:  Science       Date:  1995-07-07       Impact factor: 47.728

9.  Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells.

Authors:  X Xu; S H Kang; O Heidenreich; M Okerholm; J J O'Shea; M I Nerenberg
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Analysis of interleukin-2-dependent signal transduction through the Shc/Grb2 adapter pathway. Interleukin-2-dependent mitogenesis does not require Shc phosphorylation or receptor association.

Authors:  G A Evans; M A Goldsmith; J A Johnston; W Xu; S R Weiler; R Erwin; O M Howard; R T Abraham; J J O'Shea; W C Greene
Journal:  J Biol Chem       Date:  1995-12-01       Impact factor: 5.157

View more
  51 in total

Review 1.  Interleukin-2 signaling and inherited immunodeficiency.

Authors:  N A Cacalano; J A Johnston
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

2.  CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1.

Authors:  J J Perez-Villar; G S Whitney; M A Bowen; D H Hewgill; A A Aruffo; S B Kanner
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.

Authors:  Q Zhang; P N Raghunath; E Vonderheid; N Odum; M A Wasik
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 4.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

Review 5.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

Review 6.  Roles of TRAF3 in T cells: many surprises.

Authors:  Zuoan Yi; Alicia M Wallis; Gail A Bishop
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 7.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation.

Authors:  Wei Ding; Seung-Jae Kim; Amrithraj M Nair; Bindhu Michael; Kathleen Boris-Lawrie; Adam Tripp; Gerold Feuer; Michael D Lairmore
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells.

Authors:  Thomas Bakken; Meilan He; Mark L Cannon
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

10.  Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.

Authors:  Keke Fan; Ernest Borden; Taolin Yi
Journal:  J Interferon Cytokine Res       Date:  2009-08       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.